Aquestive Therapeutics, Inc. AQST Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s business segments — SG&A?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — SG&A of $10.98M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — SG&A changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — SG&A decreased by 42.4% year-over-year, from $19.07M to $10.98M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — SG&A?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — SG&A has grown at a 58.6% compound annual growth rate (CAGR), from $31.75M to $79.85M.
- What does business segments — SG&A mean?
- Represents the combined operating expenses related to selling, marketing, and general administrative support for the segment. This aggregate metric provides a comprehensive view of the non-production overhead required to operate the business unit. It is a key measure of the segment's overall operational efficiency and cost management performance.